We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GMRS vs. CRL: Which Stock Should Value Investors Buy Now?
Read MoreHide Full Article
Investors interested in Medical Services stocks are likely familiar with GMR Solutions Inc. (GMRS - Free Report) and Charles River Laboratories (CRL - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, GMR Solutions Inc. is sporting a Zacks Rank of #1 (Strong Buy), while Charles River Laboratories has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that GMRS likely has seen a stronger improvement to its earnings outlook than CRL has recently. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
GMRS currently has a forward P/E ratio of 6.48, while CRL has a forward P/E of 30.05. We also note that GMRS has a PEG ratio of 0.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CRL currently has a PEG ratio of 3.11.
Another notable valuation metric for GMRS is its P/B ratio of 0.7. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, CRL has a P/B of 5.08.
These are just a few of the metrics contributing to GMRS's Value grade of A and CRL's Value grade of C.
GMRS sticks out from CRL in both our Zacks Rank and Style Scores models, so value investors will likely feel that GMRS is the better option right now.
View the Zacks #1 Rank List
Image: Bigstock
GMRS vs. CRL: Which Stock Should Value Investors Buy Now?
Investors interested in Medical Services stocks are likely familiar with GMR Solutions Inc. (GMRS - Free Report) and Charles River Laboratories (CRL - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, GMR Solutions Inc. is sporting a Zacks Rank of #1 (Strong Buy), while Charles River Laboratories has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that GMRS likely has seen a stronger improvement to its earnings outlook than CRL has recently. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
GMRS currently has a forward P/E ratio of 6.48, while CRL has a forward P/E of 30.05. We also note that GMRS has a PEG ratio of 0.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CRL currently has a PEG ratio of 3.11.
Another notable valuation metric for GMRS is its P/B ratio of 0.7. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, CRL has a P/B of 5.08.
These are just a few of the metrics contributing to GMRS's Value grade of A and CRL's Value grade of C.
GMRS sticks out from CRL in both our Zacks Rank and Style Scores models, so value investors will likely feel that GMRS is the better option right now.